Last reviewed · How we verify
NCT06921785: ARTEMIDE-HCC01
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
Phase 3 trial testing Tremelimumab in Hepatocellular Carcinoma in 1,220 participants. Currently enrolling.
16 March 2029
Quick facts
| Lead sponsor | AstraZeneca |
|---|---|
| Phase | Phase 3 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 1,220 |
| Start date | 6 May 2025 |
| Primary completion | 16 March 2029 |
| Estimated completion | 14 March 2030 |
| Sites | 204 locations across Hong Kong, Italy, Japan, Taiwan, Vietnam, South Korea, Netherlands, Thailand |
Drugs / interventions tested
- Tremelimumab (TREMELIMUMAB) — full drug profile →
- Rilvegostomig
- Bevacizumab (Bevacizumab-Bvzr) — full drug profile →
- Atezolizumab (atezolizumab) — full drug profile →
Conditions studied
- Hepatocellular Carcinoma — all drugs for Hepatocellular Carcinoma →
Sponsor
AstraZeneca — full company profile →
Who can join
18 and older, any sex, with Hepatocellular Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a Phase III, randomised, open-label, sponsor-blinded, 3-arm, multicentre, global study assessing the efficacy and safety of rilvegostomig in combination with bevacizumab with or without tremelimumab compared to atezolizumab in combination with bevacizumab. This study will be conducted in participants with advanced HCC who are not amenable to curative therapy or locoregional therapy
Publications & conference data
6 peer-reviewed publications reference this trial (live from Europe PMC):
-
Combination immunotherapy in hepatocellular carcinoma: synergies among immune checkpoints, TKIs, and chemotherapy.
Dai S, Chen Y, Cai W, Dong S, et al · · 2025 · cited 11× · PMID 41013723 · DOI 10.1186/s13045-025-01739-6 -
Bispecific antibodies: unleashing a new era in oncology treatment.
Shui L, Wu D, Yang K, Sun C, et al · · 2025 · cited 6× · PMID 40760704 · DOI 10.1186/s12943-025-02390-y -
Hallmarks of liver cancer: Therapeutic implications.
Llovet JM, Pinyol R, Affo S, Yarchoan M, et al · · 2026 · cited 1× · PMID 41997132 · DOI 10.1016/j.cell.2026.03.001 -
Gastrointestinal cancer: molecular pathogenesis and targeted therapy.
Jin Y, He X, Wu Y. · · 2025 · cited 1× · PMID 41361128 · DOI 10.1186/s43556-025-00361-9 -
Global Advances in Hepatocellular Carcinoma Research and Therapy in 2025
Hu B, Gao Q. · · 2026 -
Targeting TIGIT to improve outcomes in advanced HCC.
Bejjani AC, Roayaie S, Finn RS. · · 2025 · PMID 41635625 · DOI 10.1016/j.jhepr.2025.101552
Verify or expand the search:
- PubMed search for NCT06921785
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Tremelimumab
Trials testing the same drug.
- NCT07288034 — Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatmen · Phase 2 · recruiting
- NCT07511504 — Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanc · Phase 2 · not yet recruiting
- NCT07391670 — A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durval · Phase 1 · recruiting
- NCT07166406 — Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO- · Phase 3 · recruiting
- NCT07174570 — Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer · Phase 2 · recruiting
Other recruiting trials for Hepatocellular Carcinoma
Currently open trials in the same condition.
- NCT06902246 — Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma · Phase 2 · recruiting
- NCT05842174 — Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma · Phase 1, PHASE2 · recruiting
- NCT07417397 — Adjuvant TACE in HCC With High-risk Recurrence Factors · Phase 3 · recruiting
- NCT07317414 — β-alanine in the Treatment of Advanced Hepatocellular Carcinoma · Phase 2 · recruiting
- NCT07148050 — Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimer · Phase 1 · recruiting
Other AstraZeneca trials
Trials by the same sponsor.
- NCT06998095 — Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea · not yet recruiting
- NCT07431775 — Saphnelo Use in Females of Child-bearing Potential · not yet recruiting
- NCT07516184 — Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis · NA · not yet recruiting
- NCT07279935 — Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resec · Phase 4 · not yet recruiting
- NCT07279948 — A Single-arm Observational Study to Characterize the Demographic, Clinical Features and Outcomes of a Brazilian Cohort o · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06921785 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by AstraZeneca
- Last refreshed: 9 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06921785.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing